Management of non alcoholic fatty liver disease in Ayurveda
- Conditions
- Health Condition 1: K760- Fatty (change of) liver, not elsewhere classifiedHealth Condition 2: K760- Fatty (change of) liver, not elsewhere classifiedHealth Condition 3: K760- Fatty (change of) liver, not elsewhere classifiedHealth Condition 4: E888- Other specified metabolic disorders
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Either sex aged between 18-65 years.
2.Diagnosed cases of Grade- I&II of non-alcoholic fatty liver disease as evident by fatty infiltration by Ultrasound evaluation (USG Abdomen)
3.Participants having BMI from 18.5 to 30
4.Subjects of non-alcoholic fatty liver disease with their hepatic enzymes <2 times upper normal limit.
5.Willing to provide informed consent and able to participate for 3 months in the study.
1.Any other identified cause of chronic liver disease or already taking supplementary medicine for NAFLD.
2.H/O habitual consumption of alcohol intake of >20g/day for women, >40g/day for men
3.Subjects who have a past history of Cardiac Arrhythmia, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
4.Known case of malignancy, concurrent Renal Dysfunction, uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients), Neurological disorders, severe psychiatric disorders, endocrinology or other concurrent severe disease.
5.Uncontrolled Diabetes Mellitus(HbA1C >8)
6.Subjects taking participation in any other clinical trial.
7.Pregnant or lactating women
8.Any other condition which PI think can jeopardize the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in score of Fatty Liver Index (FLI)Timepoint: baseline and at the end of treatment (90 days)
- Secondary Outcome Measures
Name Time Method to assess changes in ALT AST Serum bilirubin Total proteins & Alkaline Phosphatase. Changes in triglyceride Change in BMI change in Fatty liver index, quality of life in terms of SF 36 score and to assess any biological intolerability or adverse events and to record the number of participants with any biological intolerability or adverse event during the trial period.Timepoint: baseline and at the end of treatment (90 days).